Intravascular ultrasound-guided drug-coated balloon venoplasty for in-stent restenosis in pulmonary veins stenosis: a case report

Juan J. Portero-Portaz *, Juan G. Córdoba-Soriano , Arsenio Gallardo-López , and Jesús M. Jiménez-Mazuecos

Haemodynamics and Interventional Cardiology Unit, University Hospital of Albacete, C/ Hermanos Falcón, 02006, Albacete, Spain

Received 29 November 2020; first decision 14 January 2021; accepted 24 September 2021; online publish-ahead-of-print 6 November 2021

Background
Pulmonary veins stenosis (PVS) after atrial fibrillation radiofrequency ablation is an uncommon complication. When it occurs, percutaneous treatment is the preferred approach. There is a lack of standardized procedures, and when stenting restenosis is relatively common.

Case summary
We present a young patient with recurrence of PVS after first percutaneous treatment. The recurrence of haemoptysis and dyspnoea after treatment in PVS allowed the diagnosis of significant stenosis again in our patient. In the Heart Team, we opted for a new percutaneous treatment, using intravascular ultrasound (IVUS) to optimize the final result.

Discussion
Nowadays, percutaneous approach is preferred and among percutaneous treatments for PVS, stenting has shown better results than balloon angioplasty (BA). Despite this, experience in in-stent restenosis is limited, and there is a lack of adequate and specific material for its approach. In this case, we present the possible role of the IVUS and the drug-coated BA in this entity.

Keywords
IVUS • In-stent restenosis • Drug-coated balloon • Pulmonary vein • Atrial fibrillation • Case report

Learning points
• Restenosis is a common complication of the percutaneous treatment for radiofrequency ablation-related pulmonary vein stenosis.
• Intravascular ultrasound-guided procedures, both the index procedure and subsequent restenosis, may decrease restenosis risk.
• Drug-coated balloon angioplasty could be a good strategy when restenosis occurs in order to avoid metallic multilayering.

Introduction
Pulmonary vein stenosis (PVS) is estimated to complicate between 0.3% and 3.4% of atrial fibrillation (AF) ablation procedures. Better results have been described with stenting vs. balloon angioplasty (BA) alone for the treatment of this complication. Unfortunately, pulmonary veins restenosis (PVR) after percutaneous treatment of radiofrequency-related stenosis is a common complication. The
mechanism of PVR is poorly understood, and the reason for this lack of benefit from stenting during a second intervention is unclear. We present a case of in-stent restenosis (ISR) successfully treated with intravascular ultrasound (IVUS)-guided drug-coated BA and especially, highlighting the role that the use of IVUS may play in the management of this complication.

### Timeline

| Date      | Event                                                                 |
|-----------|-----------------------------------------------------------------------|
| May 2016  | Atrial fibrillation diagnosed.                                         |
| March 2017| Pulmonary veins radiofrequency ablation.                               |
| May 2017  | Haemoptysis and dyspnoea of new appearance.                           |
| July 2017 | Pulmonary veins stenosis (PVS) diagnosed.                              |
| August 2017| Percutaneous treatment of PVS.                                       |
| November–December 2017| In-stent restenosis in pulmonary veins and intravascular ultrasound-guided drug-coated balloon angioplasty. |
| May 2018  | One-year follow-up. No symptoms.                                       |
| Nov 2020  | No Symptoms. Sinusal rhythm.                                           |

### Case presentation

A 67-year-old woman with AF underwent pulmonary veins radiofrequency ablation in March 2017. Four months after index procedure, she was admitted with progressive dyspnoea and PVS was diagnosed using computed tomography (CT). Percutaneous treatment with BA and stent implantation was performed. Balloon-expandable cobalt-chromium stents Omnilink Elite® 10 mm × 19 mm on left superior pulmonary vein (LSPV), 8 mm × 19 mm on left inferior pulmonary vein (LIPV), and 7 mm × 16 mm on right inferior pulmonary vein (RIPV) were used.

Twenty months later, she started again with progressive dyspnoea and cough. The CT confirmed severe ISR of all treated veins, and new severe stenosis in right superior pulmonary vein (RSPV). A new percutaneous approach was decided by our Heart Team. Through the right femoral vein and transseptal access (Agilis™ sheath and BRK-1™ needle, St. Jude Medical, MN, USA) with SafeSept® wire (PressureProducts, CA, USA), a significant increased pressure gradient (20–30 mmHg on average) between pulmonary veins and left atrium was demonstrated. Intravascular ultrasound (Opticross™, Boston Scientific, MA, USA) showed severe ISR of RIPv [minimum stenotic area (MSA) 4.72 mm²], LSPV (MSA 21.4 mm²), LIPV (MSA 5.72 mm²), and severe de novo stenosis in RSPV was proved (Figure 1, Videos 1–3, and Supplementary material online, Videos S1 and S2).

With CT measures and IVUS assessment, drug-coated balloon (DCB) angioplasty was performed successfully (Table 1) with no residual gradient and good luminal result (RIPv MSA after treatment 62.3 mm², LSPV MSA after treatment 21.7 mm², and LIPV MSA after treatment 18.1 mm²). Clopidogrel 75 mg and edoxaban 60 mg daily for 3 months was used empirically. At 1-year follow-up, she has not presented new symptoms and until nowadays the patient remains in sinusal rhythm.

### Discussion

Pulmonary vein stenosis is an uncommon but potentially deadly complication after radiofrequency ablation of AF. The incidence varies from 0.3% to 3.4% and symptoms development depends on the number of veins affected and the stenosis severity. Cough, dyspnoea, and haemoptysis are the more common symptoms.

Nowadays, due to the high surgical risk, percutaneous approach is preferred and among percutaneous treatments, stenting has shown better results than BA. Recently, Suntharos et al.² published long-term outcomes (17 ± 1.98 months) of 205 patients with PVS treated by percutaneous approach between 2000 and 2016, with less restenosis rates in stented patients vs. BA [15% vs. 73%, P < 0.01, hazard ratio (HR) 5.7]. Despite the correct treatment, PVR occurs in one-third of cases with worse prognosis and higher likelihood for subsequent recurrent stenosis.³,4 Pathophysiology is not well known, but the hypothesis is that periadventitial inflammation and collagen deposition cause reactive hyperplasia and fibrosis.

Widmer et al.³ reviewed risk factors for PVR, finding higher rates in patients with more than one previous procedure (HR: 1.91; 95% CI 1.07–3.41; P = 0.01). Among intraprocedural factors, BA vs. stenting [HR: 2.77; 95% confidence interval (CI): 1.72–4.45; P < 0.001] and higher post-procedure pressure gradients, are the stronger predictors for PVR. Moreover, lower PVR rates have been demonstrated with higher pressure BA (HR: 0.87; 95% CI 0.78–0.98; P = 0.02). These intraprocedural risk factors suggest that, as in coronary angioplasty, previous vessel or plaque preparation is highly recommended. Although there are no standardized procedures for PVR percutaneous treatment, an increased risk of complications in patients treated with higher atmospheres deployment have not been described.

Taking into consideration these points, it could be suggested that a careful planification of the index procedure may significantly reduce the risk of related complications. Fender et al.⁶ had already proposed an algorithm to guide management for recurrent stenosis recommending BA predilation for ISR. In addition to these recommendations, it seems reasonable to add IVUS assessment to the management of pulmonary veins ISR. The IVUS may be a useful tool, both in the index procedure and if restenosis occurs, helping to choose the appropriate devices according to vein diameter and stenosis, and also for assessment of the stent apposition and expansion.

Our case was based on the good results of previous in vitro experiences of DCB on PV myofibroblasts inhibition,⁷ and it suggests that like in coronary ISR, DCB may have a role for PVR treatment to avoid metallic multilayer. There are a lack of large enough drug-eluting stent so bare-metal stents (BMS) have been the device of choice in pulmonary veins. It can be affirmed that, as in coronary devices, DCB angioplasty could be an alternative to a second metal layer for BMS ISR in pulmonary veins.⁸ Even though previous experience with DCB and myofibroblasts inhibition have shown good results in PVR,⁹,¹⁰ to our best knowledge, this is the first case with success percutaneous approach using DCB and IVUS in PVR.

---

1. J.J. Portero-Portaz
2. Suntharos et al.
3. Widmer et al.
4. Fender et al.
Follow-up after radiofrequency ablation of AF is neither standardized nor protocolized in most hospitals. Asymptomatic patients generally do not require imaging tests and clinical follow-up seems to be sufficient. In patients who develop symptoms suggestive of restenosis, the use of different imaging tests has been reported. In the longest series published after percutaneous treatment, it seems that CT could be the gold-standard test for follow-up because it provides anatomical information that allows diagnosis and planning future treatment. Although timing is not standardized, it seems prudent to perform a first study at least at 6 months after treatment, spacing them according to clinical follow-up. The role of transthoracic echocardiography may be limited, but transthoracic echocardiography may show indirect data of increased pressures in the right cavities, or an established pulmonary hypertension. Despite this, the use of imaging tests should be standardized in the coming years in order to achieve a correct follow-up of these patients.

Finally, the antithrombotic regimen after PV angioplasty and stenting has been extrapolated from the experience with other coronary

| Vein        | Device                      | Size (mm) | Inflation pressure (atm) | Pre/post gradient (mmHg) |
|-------------|-----------------------------|-----------|--------------------------|--------------------------|
| LSPV        | Pantera Lux™ (Biotronik, Berlin, Germany) | 4 x 15    | 8                        | 13/6                     |
| LIPV        | Ranger™ (Boston Scientific, Massachusetts, USA) | 8 x 30    | 6                        | 20/3                     |
| RSPV        | Pantera Lux™ (Biotronik, Berlin, Germany) | 4.0/4.0 x 15 | 8/8                      |                          |
| RSPV*       | Mustang™ (Boston Scientific, Massachusetts, USA) | 10 x 40   | 8                        | 20/4                     |
| RIPV        | Ranger™ (Boston Scientific, Massachusetts, USA) | 7 x 30    | 6                        | 18/3                     |

*In RSPV two drug coated balloons were inflated in parallel due to the lack of appropriate size coated balloon, finally a peripheral regular balloon angioplasty was realized.
and intracardiac devices, without specific studies on this question. In our case, we decided to treat the patient with clopidogrel and edoxaban during the first 6 months after the procedure, maintaining only anticoagulation after that period.

**Conclusion**

Recurrent PVS following a successful percutaneous intervention is common. The use of IVUS for stenting index procedure and to guide DCB angioplasty when restenosis occurs, seems to be an effective and safe strategy avoiding metallic multilayering in PV.

**Lead author biography**

Juan J. Portero-Portaz received his medical degree from the University of Castilla La-Mancha, Spain. Currently, he is doing a fellowship in haemodynamics and interventional cardiology at the General University Hospital of Albacete, Spain.

**Supplementary material**

Supplementary material is available at European Heart Journal - Case Reports online.

**Slide sets:** A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data.

**Consent:** The author/s confirm that written consent for submission and publication of this case report including images and associated text has been obtained from the patient in line with COPE guidance.

**Conflict of interest:** The authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements) or non-financial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.
**Funding:** None declared.

**References**

1. Widmer RJ, Fender EA, Hodge DO, Monahan KH, Peterson LA, Holmes DR Jr et al. Contributors toward pulmonary vein restenosis following successful intervention. *JACC Clin Electrophysiol* 2018;4:547–552.

2. Suntharos P, Worley SE, Liu W, Siperstein M, Prieto LR. Long-term outcome of percutaneous intervention for pulmonary vein stenosis after pulmonary vein isolation procedure. *Catheter Cardiovasc Interv* 2020;95:389–397.

3. Fender E, Widmer RJ, Hodge DO, Cooper GM, Monahan KH, Peterson LA et al. Severe pulmonary vein stenosis resulting from ablation for atrial fibrillation: presentation, management, and clinical outcomes. *Circulation* 2016;134:1812–1821.

4. Fender EA, Widmer RJ, Monahan KH, Peterson LA, Holmes DR, Packer DL. TCT-739 management of recurrent pulmonary vein stenosis. *J Am Coll Cardiol* 2015;66:E301–E302.

5. Holmes DR, Monahan KH, Packer D. Pulmonary vein stenosis complicating ablation for atrial fibrillation: clinical spectrum and interventional considerations. *JACC Cardiovasc Interv* 2009;2:267–276.

6. Fender EA, Widmer RJ, Mahowald MK, Hodge DO, Packer DL, Holmes DR. Recurrent pulmonary vein stenosis after successful intervention: prognosis and management of restenosis. *Catheter Cardiovasc Interv* 2020;95:954–958.

7. Callahan R, Kieran MW, Baird CW, Colan SD, Gauvreau K, Ireland CM et al. Adjunct targeted biologic inhibition agents to treat aggressive multivessel intraluminal pediatric pulmonary vein stenosis. *J Pediatr* 2018;198:29–35.

8. Alfonso F, Pérez-Vazcayo MJ, Cárdenas A, García del Blanco B, Seidelberg B, Iñiguez A et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). *J Am Coll Cardiol* 2014;63:1378–1386.

9. DeSimone CV, Holmes DR Jr, Ebirí E, Syed FF, Ladewig DJ, Mikell SB et al. Direct pulmonary vein ablation with stenosis prevention therapy. *J Cardiovasc Electrophysiol* 2015;26:1000–1006.

10. Rosenberg J, Fisher WG, Guerrero M, Smart S, Levisay J, Feldman T et al. Drug-coated balloon venoplasty for in-stent restenosis in a patient with recurrent pulmonary vein stenosis post ablation for atrial fibrillation: initial experience with a new treatment technique. *J Invasive Cardiol* 2016;28:E44–E48.